Shore Capital reiterated their buy rating on shares of AstraZeneca (LON:AZN – Free Report) in a research report report ...

JPMorgan Chase & Co. reissued their overweight rating on shares of AstraZeneca (LON:AZN – Free Report) in a report issued on ...

Symbicort brought in worldwide sales of $2.7 billion last year, with $1.1 billion of that coming from the US market, where an authorised generic sold under license from AZ has been available since ...

A US court has upheld AstraZeneca’s patents on its respiratory drug Symbicort, blocking cheaper competition for the ageing blockbuster. The US District Court for the Northern District of West ...

Drugmaker Viatris beat Wall Street estimates for third-quarter profit and revenue on Thursday, helped by strong demand for its new generic asthma and ADHD drugs, among others, sending its shares up 2.

Key Takeaways Zacks earnings estimates for AstraZeneca are currently at $4.06 per share. However, the earnings picture ...

Viatris Inc. VTRS delivered third-quarter 2024 adjusted earnings of 75 cents per share, which beat the Zacks Consensus ...

Q3 2024 Earnings Conference Call November 6, 2024 8:30 AM ETCompany ParticipantsBill Szablewski - Head of Capital ...

The Spanish COPD guidelines recommend treatment of the mixed COPD–asthma phenotype with ICS and a long-acting bronchodilator (LABD) as a first option to improve lung function, respiratory ...

Verona的COPD药物商业化超预期的背后，折射出的是COPD适应症药物迭代的迫切需求，上一个时代的激素类药物和β受体激动剂都因为作用效果较为广谱而有众多副反应，针对PDE靶点的COPD药物已经初显峥嵘，之后还有TSLP靶点的单抗作为“预备队”，C ...